{"id":"W3152750473","doi":"10.1016/s1470-2045(21)00081-4","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Novartis Pharma; EMD Serono; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Johnson and Johnson; Genentech; Eisai; SkylineDx; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Pfizer; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; EUSA Pharma; Roche; Novartis; GlaxoSmithKline; Amgen; Qbiotics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Hazard ratio; Placebo; Internal medicine; Quality of life (healthcare); Population; Clinical trial; Adverse effect; Oncology; Melanoma; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006511331,0.0003884819,0.00400388,0.0002112529,0.0001603684,0.00002750351,0.0004135651,0.0004986662,0.0008347452],"category_scores_gemma":[0.002413165,0.0002749309,0.00050328,0.0007206122,0.0003636527,0.00007582658,0.000114583,0.001000783,0.00002122577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000713361,"about_ca_system_score_gemma":0.003659599,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0100671,"about_ca_topic_score_gemma":0.009628176,"domain_scores_codex":[0.991465,0.00349372,0.002959059,0.0006932384,0.0005620073,0.0008269158],"domain_scores_gemma":[0.9910677,0.005737509,0.001524064,0.001191945,0.0002373951,0.0002413732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9789946,0.001363177,0.00003293906,0.00007483942,0.001700216,0.0002894533,0.002843254,0.0000317415,0.006147485,0.0002407844,0.003523436,0.004758094],"study_design_scores_gemma":[0.9756864,0.005294787,0.0004900746,0.0001533304,0.0002368999,0.00002427951,0.001100368,0.0003192422,0.0008864387,0.00006260873,0.0154812,0.0002643981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9577507,0.006403362,0.00003069005,0.02118457,0.002084604,0.005310963,0.0004506303,0.0001007153,0.006683711],"genre_scores_gemma":[0.9918661,0.002041897,0.000155982,0.001970737,0.001141243,0.0004714007,0.0008804277,0.00004852422,0.001423736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0341153,"threshold_uncertainty_score":0.9999703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1698307409166575,"score_gpt":0.4317912640571682,"score_spread":0.2619605231405107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}